Aevi Genomic Medicine is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, dedicated to developing innovative therapies for pediatric onset and life-altering diseases. Its lead product candidate, AEVI-002, is an anti-LIGHT monoclonal antibody currently undergoing Phase Ib clinical trials for the treatment of severe pediatric onset Crohn’s disease. The company is also advancing AEVI-005, another monoclonal antibody, which is in preclinical research for autoimmune pediatric diseases. Additionally, Aevi is exploring the anti-seizure potential of AEVI-004 as part of the National Institutes of Health Epilepsy Treatment Screening Program. The company leverages an internal genomics platform in collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia to harness genetic discoveries for therapeutic development. Founded in 2000 and originally known as Medgenics, Aevi Genomic Medicine officially adopted its current name in December 2016.
neuroFix Therapeutics, LLC, the developer of NFC-1, a first-in-class, non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator entering Phase 2/3 for the treatment of mGluR network mutation positive Attention Deficit Hyperactivity Disorder (mGluR+ ADHD), as well as neuropsychiatric symptoms resulting from a related rare genetic disorder, 22q11.2 Deletion Syndrome (22q11.2 DS).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.